Jeffrey Skinner
No más puestos en curso
Fortuna: 91 140 $ al 30/04/2024
Perfil
Jeffrey Skinner worked as the Director of Business Development at SteriMax, Inc. from 2012 to 2014.
He then worked as the Vice President of Business Development at ChitogenX, Inc. After that, he worked as the Vice President of Business Development at Valeo Pharma, Inc. from 2014 to 2023.
Mr. Skinner received his undergraduate degree and MBA from the University of Western Ontario in 1997 and 1999, respectively.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VALEO PHARMA INC CLASS A
1.42% | 15/03/2023 | 1 402 150 ( 1.42% ) | 91 140 $ | 30/04/2024 |
Antiguos cargos conocidos de Jeffrey Skinner.
| Empresas | Cargo | Fin |
|---|---|---|
| VALEO PHARMA INC. | Corporate Officer/Principal | 01/07/2023 |
SteriMax, Inc.
 SteriMax, Inc. Pharmaceuticals: MajorHealth Technology SteriMax, Inc. provides pharmaceutical products and services. The firm specializes in the development, production, marketing and distribution of essential hospital and retail pharmacy products to the Canadian healthcare market. Its products include BaciJect, Bupivacaine Injection BP, ceFAZolin for Injection, and AcetaZOLAMIDE for Injection USP. The company was founded by Mahen J. Acharya and is headquartered in Oakville, Canada. | Corporate Officer/Principal | 01/07/2014 |
| CHITOGENX INC. | Corporate Officer/Principal | - |
Formación de Jeffrey Skinner.
| University of Western Ontario | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| CHITOGENX INC. | Health Technology |
| VALEO PHARMA INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
SteriMax, Inc.
SteriMax, Inc. Pharmaceuticals: MajorHealth Technology SteriMax, Inc. provides pharmaceutical products and services. The firm specializes in the development, production, marketing and distribution of essential hospital and retail pharmacy products to the Canadian healthcare market. Its products include BaciJect, Bupivacaine Injection BP, ceFAZolin for Injection, and AcetaZOLAMIDE for Injection USP. The company was founded by Mahen J. Acharya and is headquartered in Oakville, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Jeffrey Skinner